Literature DB >> 21078939

Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Sebastiaan J van Hal1, David L Paterson.   

Abstract

The prevalence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) is 1.3% in published studies. Clinical associations include high-inoculum infections and glycopeptide failure, with hVISA infections associated with a 2.37-times-greater failure rate (95% confidence interval [CI], 1.53 to 3.67) compared to vancomycin-sensitive Staphylococcus aureus (VSSA) infections. Despite this, 30-day mortality rates were similar to those for VSSA infections (odds ratio [OR], 1.18; 95% CI, 0.81 to 1.74). The optimal therapy for hVISA requires further study.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21078939      PMCID： PMC3019654          DOI： 10.1128/AAC.01133-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  61 in total

1.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

2.  Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features.

Authors:  Olivier Denis; Claire Nonhoff; Baudouin Byl; Christiane Knoop; Sophie Bobin-Dubreux; Marc J Struelens
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

3.  Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.

Authors:  R K C Fong; J Low; T H Koh; A Kurup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-22       Impact factor: 3.267

4.  The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand.

Authors:  Aroonlug Lulitanond; Chulapan Engchanil; Prajuab Chaimanee; Malai Vorachit; Teruyo Ito; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

5.  Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

Authors:  K C Horne; B P Howden; E A Grabsch; M Graham; P B Ward; S Xie; B C Mayall; P D R Johnson; M L Grayson
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

6.  Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.

Authors:  Adina C Musta; Kathleen Riederer; Stephen Shemes; Patrick Chase; Jinson Jose; Leonard B Johnson; Riad Khatib
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

7.  Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand.

Authors:  John D Turnidge; Despina Kotsanas; Wendy Munckhof; Sally Roberts; Catherine M Bennett; Graeme R Nimmo; Geoffrey W Coombs; Ronan J Murray; Benjamin Howden; Paul D R Johnson; Kate Dowling
Journal:  Med J Aust       Date:  2009-10-05       Impact factor: 7.738

8.  Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.

Authors:  Wenjia Sun; Hongbin Chen; Yudong Liu; Chunjiang Zhao; Wright W Nichols; Minjun Chen; Jianzhong Zhang; Yue Ma; Hui Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

Authors:  Yasmin Maor; Michal Hagin; Natasha Belausov; Nathan Keller; Debbi Ben-David; Galia Rahav
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

10.  Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Benjamin P Howden; Danielle J Smith; Ashley Mansell; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  BMC Microbiol       Date:  2008-02-27       Impact factor: 3.605
View more
  56 in total

1.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 3.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 4.  Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.

Authors:  Natasha E Holmes; Paul D R Johnson; Benjamin P Howden
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

5.  Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.

Authors:  Henry Wong; Christine Watt; Sameer Elsayed; Michael John; Glen Johnson; Kevin Katz; Sigmund Krajden; Christine Lee; Tony Mazzulli; Krystyna Ostrowska; David Richardson; Baldwin Toye; Christie Vermeiren; Deborah Yamamura; Andrew E Simor
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

6.  Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Federico Pea; Piergiorgio Cojutti; Nicola Petrosillo; Mario Furlanut; J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-09       Impact factor: 5.191

7.  Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.

Authors:  A Kirby; C Edwards; C M Broughton; N J Williams
Journal:  Infection       Date:  2011-04-01       Impact factor: 3.553

8.  Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.

Authors:  Yong Pil Chong; Ki-Ho Park; Eun Sil Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

9.  Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Authors:  Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Accessory gene regulator (agr) dysfunction in Staphylococcus aureus bloodstream isolates from South Korean patients.

Authors:  Yong Pil Chong; Eun Sil Kim; Su-Jin Park; Ki-Ho Park; Tark Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Jin-Yong Jeong; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.